Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Odd L. Gammelgaard"'
Autor:
Odd L. Gammelgaard, Mikkel G. Terp, Alexei F. Kirkin, Simone Johansen, Sofie Traynor, Henriette Vever, Per Guldberg, Annette R. Kodahl, Morten F. Gjerstorff, Henrik J. Ditzel
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-16 (2024)
Abstract Background Adoptive cell transfer cancer immunotherapy holds promise for treating disseminated disease, yet generating sufficient numbers of lymphocytes with anti-cancer activity against diverse specificities remains a major challenge. We re
Externí odkaz:
https://doaj.org/article/b15051babf3e4694bceb90e2ee16d652
Publikováno v:
Molecular Oncology, Vol 15, Iss 12, Pp 3299-3316 (2021)
RAS‐MAPK signaling promotes immune evasion and cancer cell survival, and MAPK inhibitors (MAPKis) are frequently used as cancer therapies. Despite progress elucidating the direct effects of MAPKi on immune cells, their indirect effect on the tumor
Externí odkaz:
https://doaj.org/article/f3d6962653184d478d74f58cf2f92dc3
Autor:
Henrik J Ditzel, Christa E Müller, Odd L Gammelgaard, Mikkel G Terp, Christian Renn, Aran F Labrijn, Oliver Hamaker, Aaraby Y Nielsen, Henriette Vever, Soren WK Hansen, Morten F Gjerstorff, Paul WHI Parren
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Immunosuppressive extracellular adenosine is generated by the enzymatic activity of CD73. In preclinical models, antibodies (Abs) targeting different epitopes on CD73 exert anticancer activity through distinct mechanisms such as inhibition
Externí odkaz:
https://doaj.org/article/545f0eb7e81a46de9104ffcb29d1c784
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
CDK4/6 inhibitors in combination with endocrine therapy has shown efficacy in ER + breast cancer patients but resistance can occur. Here, the authors demonstrate that co-targeting CDK4/6 and AKT with endocrine therapy prevents acquired resistance and
Externí odkaz:
https://doaj.org/article/73e69d21bd364412a70101afb76ad7da
Publikováno v:
Molecular Oncology, Vol 12, Iss 10, Pp 1797-1810 (2018)
Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer ce
Externí odkaz:
https://doaj.org/article/65d3998ca8fe41e9845f10ffcec098f5
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/df7e78eab9c643b4bcc917eea8a3ff30
Publikováno v:
Molecular Oncology, Vol 15, Iss 12, Pp 3299-3316 (2021)
Molecular Oncology
Terp, M G, Gammelgaard, O L, Vever, H, Gjerstorff, M F & Ditzel, H J 2021, ' Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer : combined targeting could improve outcomes ', Molecular Oncology, vol. 15, no. 12, pp. 3299-3316 . https://doi.org/10.1002/1878-0261.13046
Molecular Oncology
Terp, M G, Gammelgaard, O L, Vever, H, Gjerstorff, M F & Ditzel, H J 2021, ' Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer : combined targeting could improve outcomes ', Molecular Oncology, vol. 15, no. 12, pp. 3299-3316 . https://doi.org/10.1002/1878-0261.13046
RAS‐MAPK signaling promotes immune evasion and cancer cell survival, and MAPK inhibitors (MAPKis) are frequently used as cancer therapies. Despite progress elucidating the direct effects of MAPKi on immune cells, their indirect effect on the tumor
Autor:
Morten F. Gjerstorff, Sofie Traynor, Odd L. Gammelgaard, Simone Johansen, Christina B. Pedersen, Henrik J. Ditzel, Mikkel G. Terp
Publikováno v:
Cancers; Volume 14; Issue 24; Pages: 6153
The pivotal role of myeloid-derived suppressive cells (MDSCs) in cancer has become increasingly apparent over the past few years. However, to fully understand how MDSCs can promote human tumor progression and to develop strategies to target this cell
Autor:
Odd L Gammelgaard, Mikkel G Terp, Christian Renn, Aran F Labrijn, Oliver Hamaker, Aaraby Y Nielsen, Henriette Vever, Soren WK Hansen, Morten F Gjerstorff, Christa E Müller, Paul WHI Parren, Henrik J Ditzel
Publikováno v:
Journal for ImmunoTherapy of Cancer, 10(9). BMJ PUBLISHING GROUP
BackgroundImmunosuppressive extracellular adenosine is generated by the enzymatic activity of CD73. In preclinical models, antibodies (Abs) targeting different epitopes on CD73 exert anticancer activity through distinct mechanisms such as inhibition